| Original language | English |
|---|---|
| Pages (from-to) | e67 |
| Number of pages | 1 |
| Journal | The Lancet Oncology |
| Volume | 20 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 2019 |
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy: who and how? - Authors' reply
Linda M Henricks, Carin A T C Lunenburg, Annemieke Cats, Ron H J Mathijssen, Henk-Jan Guchelaar, Jan H M Schellens
- Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, Netherlands.
- Netherlands Cancer Institute
- Department of Gastrointestinal Oncology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
- Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Netherlands.
Research output: Contribution to journal › Article › Academic › peer-review